Skip to main content
SpringerLink
Log in

O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Factor VIII (FVIII) is an important cofactor in the blood coagulation cascade. A deficiency or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding disorder. FVIII circulates in plasma as a heterodimer comprising 6 domains (heavy chain, A1-A2-B and light chain A3-C1-C2). Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, ∼15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein. Neutralizing antibodies to epitopes in the lipid binding region of FVIII are commonly identified in patients' plasma. In this report, we investigated the effect of O-phospho-L-serine (OPLS), which binds to the lipid bindinding region, on the immunogenicity of B domain deleted recombinant factor VIII (BDDrFVIII). Sandwich enzyme-linked immunosorbent assay (ELISA) studies showed that OPLS specifically bind to the lipid binding region, localized in the C2 domain of the coagulation factor. Size exclusion chromatography and fluorescence anisotropy studies showed that OPLS interfered with the aggregation of BDDrFVIII. Immunogenicity of free-vs BDDrFVIII-OPLS complex was evaluated in a murine model of hemophilia A. Animals administered subcutaneous (sc) injections of BDDrFVIII-OPLS had lower neutralizing titers compared with animals treated with BDDRFVIII alone. Based on these studies, we hypothesize that specific molecular interactions between OPLS and BDDrFVIII may improve the stability and reduce the immunogenicity of BDDrFVIII formulations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaufiman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.J Biol Chem. 1988;263:6352–6362.

    Google Scholar 

  2. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor.J Thromb Haemost. 2005;3:1257–1265.

    Article  PubMed  CAS  Google Scholar 

  3. Kaufman RJ. Biological regulation of factor VIII activity.Annu Rev Med. 1992;43:325–339.

    Article  PubMed  CAS  Google Scholar 

  4. Larner AJ. The molecular pathology of haemophilia.Q J Med. 1987;63:473–491.

    PubMed  CAS  Google Scholar 

  5. Klinge J, Ananyeva NM, Hauser CA, Saenko EL. Hemophilia A—from basic science to clinical practice.Semin Thromb Hemost. 2002;28:309–322.

    Article  PubMed  CAS  Google Scholar 

  6. Lollar P. Molecular characterization of the immune response to factor VIII.Vox Sang. 2002;83:403–408.

    PubMed  CAS  Google Scholar 

  7. Fijnvandraat K, Bril WS, Voorberg J. Immunobiology of inhibitor development in hemophilia A.Semin Thromb Hemost. 2003;29:61–68.

    Article  PubMed  CAS  Google Scholar 

  8. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+T-cell epitope repertoire on the C2 domain of coagulation factor VIII.J Thromb Haemost. 2003;1:1777–1784.

    Article  PubMed  CAS  Google Scholar 

  9. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5A resolution.Nature. 1999;402:439–442.

    Article  PubMed  CAS  Google Scholar 

  10. Pratt KP, Qian J, Ellaban E, et al. Immodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.Thromb Haemost. 2004;92:522–528.

    PubMed  CAS  Google Scholar 

  11. Purohit VS, Jr, Ramani K, Jr, Sarkar R, Jr, Kazazian HH, Jr, Balasubramanian SV. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.J Biol Chem. 2005;280:17593–17600.

    Article  PubMed  CAS  Google Scholar 

  12. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.Proc Natl Acad Sci USA. 1986;83:5939–5942.

    Article  PubMed  CAS  Google Scholar 

  13. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical immunological, and in vivo functional characterization of B-domain-deleted factor VIII.Blood. 1993;81:2925–2935.

    PubMed  CAS  Google Scholar 

  14. Ramani K, Balasubramanian SV. Fluorescence properties of Laurdan in cochleate phases.Biochim Biophys Acta. 2003;1618:67–78.

    Article  PubMed  CAS  Google Scholar 

  15. Over J. Methodology of the one-stage assay of Factor VIII (VIII:C).Scand J Haematol Suppl. 1984;41:13–24.

    PubMed  CAS  Google Scholar 

  16. Ramani K, Purohit V, Middaugh CR, Balasubramanian SV. Aggregation kinetics of recombinant human FVIII (rFVIII).J Pharm Sci. 2005;94:2023–2029.

    Article  PubMed  CAS  Google Scholar 

  17. Lakowicz J.Principles of Fluorescence Spectroscopy. New York, NY: Kluwer Academic/Plenum; 1999.

    Google Scholar 

  18. Wu H, Reding M, Qian J, et al. Mechanism of the immune response to human factor VIII in murine hemophilia A.Thromb Haemost. 2001;85:125–133.

    PubMed  CAS  Google Scholar 

  19. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.Thromb Haemost. 1995;73:247–251.

    PubMed  CAS  Google Scholar 

  20. Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.J Biol Chem. 1998;273:27918–27926.

    Article  PubMed  CAS  Google Scholar 

  21. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine.Biochemistry. 1993;32:9577–9585.

    Article  PubMed  CAS  Google Scholar 

  22. Purohit VS, Ramani K, Kashi RS, Durrani MJ, Kreiger TJ, Balasubramanian SV. Topology of factor VIII bound to phosphatidylserine-containing model membranes.Biochim Biophys Acta. 2003;1617:31–38.

    Article  PubMed  CAS  Google Scholar 

  23. Griffin BD, Micklem LR, McCann MC, James K, Pepper DS. The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII.Thromb Haemost. 1986;55:40–46.

    PubMed  CAS  Google Scholar 

  24. Zhai X, Srivastava A, Drummond DC, Daleke D, Lentz BR. Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va.Biochemistry. 2002;41:5675–5684.

    Article  PubMed  CAS  Google Scholar 

  25. Li X, Gabriel DA. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.Biochemistry. 1997;36:10760–10767.

    Article  PubMed  CAS  Google Scholar 

  26. Ramani K, Purohit VS, Miclea RD, Middaugh CR, Balasubramanian SV. Lipid binding region (2303–2332) is involved in aggregation of recombinant human FVIII (rFVIII).J Pharm Sci. 2005;94:1288–1299.

    Article  PubMed  CAS  Google Scholar 

  27. Falls LA, Furie B, Furie BC. Role of phosphatidylethanolamine in assembly and function of the factor IXa-factor VIIIa complex on membrane surfaces.Biochemistry. 2000;39:13216–13222.

    Article  PubMed  CAS  Google Scholar 

  28. Grillo AO, Edwards KL, Kashi RS, et al. Conformatinal origin of the aggregation of recombinant human factor VIII.Biochemistry. 2001;40:586–595.

    Article  PubMed  CAS  Google Scholar 

  29. Derrick TS, Kashi RS, Durrani M, Jhingan A, Middaugh CR. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII.J Pharm Sci. 2004;93:2549–2557.

    Article  PubMed  CAS  Google Scholar 

  30. Fatouros A, Liden Y, Sjostrom B. Recombinant factor VIII SQ—stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue.J Pharm Pharmacol. 2000;52:797–805.

    Article  PubMed  CAS  Google Scholar 

  31. Wang W, Kelner DN. Correlation of rFVIII inactivation with aggregation in solution.Pharm Res. 2003;20:693–700.

    Article  PubMed  CAS  Google Scholar 

  32. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. Inhibition of stress-induced aggregation of protein therapeutics.Methods Enzymol. 1999;309:236–255.

    Article  PubMed  CAS  Google Scholar 

  33. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma.Proc Natl Acad Sci USA. 1998;95:14142–14146.

    Article  PubMed  CAS  Google Scholar 

  34. Kendrick BS, Chang BS, Arakawa T, et al. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state.Proc Natl Acad Sci USA. 1997;94:11917–11922.

    Article  PubMed  CAS  Google Scholar 

  35. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography.Blood. 2002;99:1215–1223.

    Article  PubMed  CAS  Google Scholar 

  36. Qian J, Jr, Borovok M, Jr, Bi L, Jr, Kazazian HH, Jr, Hoyer LW. Inhibitor antibody development and T-cell response to human factor VIII in murine hemophilia A.Thromb Haemost. 1998;81:240–244.

    Google Scholar 

  37. Hoffimann PR, Kench JA, Vondracek A, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo.J Immunol. 2005;174:1393–1404.

    Google Scholar 

  38. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH.J Clin Endocrinol Metab. 1980;51:691–697.

    Article  PubMed  CAS  Google Scholar 

  39. Rosenberg AS. Effects of protein aggregates: an immunologic perspective.AAPS J. 2006;8:E501-E507.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular & Cellular Biophysics and Biochemistry, Roswell Park Cancer Institute, Buffalo, NY

    Razvan D. Miclea & Sathy V. Balu-Iyer

  2. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 14260, Buffalo, NY

    Vivek S. Purohit & Sathy V. Balu-Iyer

Authors
  1. Razvan D. Miclea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek S. Purohit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sathy V. Balu-Iyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sathy V. Balu-Iyer.

Additional information

Published: June 29, 2007

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miclea, R.D., Purohit, V.S. & Balu-Iyer, S.V. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. AAPS J 9, 28 (2007). https://doi.org/10.1208/aapsj0902028

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/aapsj0902028

Keywords

Search

Navigation